insufficient for accurate diagnosis of acute pancreatitis and cannot adequately diagnose concurrent local or remote sequelae, including portal vein thromboses.
Three-phase computed tomographic angiography (CTA) has been shown to be a rapid and accurate method for the diagnosis of acute pancreatitis in people. 6 In a previous study, people with CT evidence of pancreatic necrosis (ie, heterogeneous contrast enhancement) had a 23% mortality rate and 82% morbidity rate compared to 0% mortality rate and 6% morbidity in the absence of necrosis (ie, homogeneous pancreatic contrast enhancement). 7, 8 In addition, CTA has shown overall accuracy of 87% and sensitivity of 100% in diagnosing surgically confirmed pancreatic necrosis in humans. [8] [9] [10] [11] The CTA findings are utilized to determine the course of treatment in human patients diagnosed with acute pancreatitis. [6] [7] [8] [9] A previous pilot study at our institution using CTA to evaluate 10 dogs with acute pancreatitis identified multiple changes in the CT appearance of the pancreas, peripancreatic tissues, and adjacent vessels that may be important in the prognostication of affected patients. 12 Specifically, those patients with more heterogeneous contrast enhancement appeared to have worse outcome than those with homogeneous contrast enhancement. 12 Computed tomographic angiography also diagnosed 3 of the 10 dogs from the aforementioned study as having portal vein thrombosis, a sequela of acute pancreatitis, which was not seen during ultrasonographic examination. 12 A larger study is necessary to further elucidate how these changes in contrast enhancement correspond with prognosis and outcome and to further evaluate and identify sequelae of pancreatitis (eg, venous and arterial thromboses) using CTA.
Our goals were 2-fold: first, to compare CTA to US as a diagnostic tool in a larger population of dogs with suspected acute pancreatitis and, second, to evaluate CTA as a prognostic tool in this same population of dogs. We hypothesized that, in comparison to US, CTA in sedated dogs will allow for better visualization of the entire pancreas, better identify sequelae, including portal vein thrombosis, and better identify changes indicative of necrotizing pancreatitis, specifically a heterogeneous contrast enhancement pattern. We also hypothesized that CTA can be used to predict patient outcome and that specific findings identified on CTA (ie, heterogeneous contrast enhancement)
will be associated with worse prognosis.
| MATERIALS AND METHODS

| Study overview
This cross-sectional, prospective study consisted of 26 dogs, 10 of which had been included in a previous pilot study. 12 The 2nd portion of the study was conducted from March 2016 to April 2017.
The study protocol was approved by the Institutional Animal Care and Use Committee (IACUC), and all dog owners gave informed consent. Dogs were considered for inclusion if 2 of 3 of the following criteria were fulfilled: (1) 
| Abdominal ultrasonography
An abdominal ultrasonographic examination was performed for inclusion or repeated within 24 hours of inclusion using a B-mode US machine (Siemens Accuson Antares; Siemens Medical Solutions, Mountain View, California or Toshiba Aplio 500; Canon Medical Systems, Tustin, California) by a 2nd-or 3rd-year radiology resident or a board-certified radiologist. All US examinations were performed using a standard scanning protocol developed at our institution, and examinations performed by a radiology resident were later reviewed by a board-certified radiologist. All examinations were performed with the patient in dorsal or lateral recumbency. were acquired in a cranial to caudal direction followed by venous phase images in a caudal to cranial direction. Delayed phase images
| Computed tomographic angiography
were acquired approximately 2-3 minutes post-contrast injection. All images (pre-contrast, arterial, venous, and delayed) were acquired using 2-mm thick slices in a standard algorithm.
| Additional tests
All dogs had a CBC, serum biochemistry, and spec cPL performed at the time of enrollment, if not previously performed. US-guided aspirates of the pancreas using 22-gauge needles were performed after CTA in an attempt to identify pancreatic necrosis, fibrosis, inflammation, or abscess and to eliminate the possibility of pancreatic neoplasia.
When different contrast enhancement patterns were identified in regions of the pancreas, an attempt was made to sample these regions.
The clinical pathologists on duty reviewed the cytologic samples.
| Data collection
A radiologist (A.J.M.) and a 3rd-year radiology resident (J.M.F.)
reviewed all CTA and US examinations with careful attention to the pancreas and peripancreatic tissues. The 2 imaging procedures were compared to determine the potential added diagnostic value and clinical relevance of CTA compared to US. The CTA and US findings were analyzed in terms of severity of disease, attenuation and echogenicity of the pancreas, contrast enhancement of the pancreas, size of the pancreas, changes to the peripancreatic tissues, and the presence of specific sequelae. Ultrasonographic and CTA pancreatic enlargement were determined using previously reported reference ranges. CTA and according to previously reported reference ranges for size. 15 The dogs recruited in the 2nd portion of the study were followed for a minimum of 9 months, and all owners were contacted at that time. Medical records also were evaluated in all dogs to determine outcome variables, including duration of hospitalization, number of relapses, time until death, and long-term complications that may be associated with pancreatitis (eg, exocrine pancreatic insufficiency). Clinical outcome was determined by review of the medical records and client communications.
| Statistical analysis
The data from CTA and US were dependent data and categorical;
hence, most of the analyses were performed using 
| Ultrasound imaging findings
The Seventeen of the 26 dogs had free peritoneal fluid.
| Computed tomographic angiography imaging findings
The entirety of the pancreas was visualized in all dogs using CTA. 
| Comparison of Computed tomographic angiography and US imaging findings
Overall, CTA better visualized the entirety of the pancreas than did US. The entirety of the pancreas was visualized in 100% of the dogs by CTA, whereas the entirety of the pancreas was only visualized by US in 73% of the dogs. Computed tomographic angiography did not significantly identify changes indicative of pancreatitis, including pancreatic enlargement, mesenteric changes (P = .12), or changes in attenuation and echogenicity better than US (P = .14).
Comparison between detection of sequelae by CTA versus US is shown in Table 1 . Portal vein thrombosis was significantly more likely to be detected by CTA when compared to US (P = .004).
Computed tomographic angiography identified portal vein thrombi When evaluating CTA as a prognostic tool, heterogeneous contrast enhancement and the presence of specific sequelae were analyzed individually to determine a correlation between these variables and outcome variables, including duration of hospitalization, number of relapses, and time until death. This analysis is shown in Table 2 . Heterogeneous contrast enhancement was significantly associated with longer hospitalization (P = .01). Dogs with homogeneous contrast enhancement of the pancreas had a mean hospitalization of 2.8 days, whereas those dogs with heterogeneous contrast enhancement of any portion of the pancreas had a mean duration of hospitalization of 4.8 days. Dogs with heterogeneous contrast enhancement also were significantly more likely to be hospitalized for ≥5 days (P = .03).
Dogs with portal vein thrombosis had a significantly longer duration of hospitalization. Mean hospitalization was 3 days in dogs without portal vein thrombosis and 4.5 days in dogs with portal vein thrombosis (P = .05), and dogs with portal vein thrombosis were significantly more likely to be hospitalized for ≥5 days (P = .03). Finally, dogs with lymphadenomegaly identified by CT also were significantly more likely to be hospitalized for ≥5 days (P = .003), and median time until death was significantly longer in dogs with lymphadenomegaly (P = .03).
The remaining variables evaluated were not significantly associ- 
| DISCUSSION
Similar to human patients with pancreatitis, 3-phase CTA is a useful tool in the diagnosis and prognostication of acute pancreatitis in dogs. 8, 16, 17 Evidence of heterogeneous pancreatic contrast enhancement on CTA is associated with pancreatic necrosis and worse prognosis in dogs as in people. 7, 8, [18] [19] [20] In our study, dogs with heterogeneous contrast enhancement on CTA also had a significantly longer duration of hospitalization including the likelihood to be hospitalized for ≥5 days, had an increased number of relapses, and were significantly more likely to have portal vein thrombosis. Our findings also confirm that CTA is significantly more likely to detect the presence of portal vein thrombosis than is US. Also, patients with heterogeneous contrast enhancement had significantly increased spec cPL when compared to those with homogeneous pancreatic contrast enhancement. To the best of our knowledge, ours is the 1st reported correlation between a serum assay for the detection of pancreatitis and CTA findings in dogs.
The 1st goal of our study was to determine if CTA is more accurate than US in the detection of pancreatitis, pancreatic changes that may indicate necrosis (ie, heterogeneous contrast enhancement), and sequelae of pancreatitis. Although CTA allowed better visualization of the entire pancreas than did US, it was not better at identifying those animals suffering from acute pancreatitis. Because US examination is operator dependent, this finding may indicate that experienced sonographers were performing the US studies at our institution. Less experienced sonographers may have more difficulty in identifying the entire pancreas, and CTA may be a better diagnostic imaging tool in certain settings. The increased utility of CTA when compared to US is a result of its ability to detect changes that may indicate more severe forms of acute pancreatitis and its ability to detect sequelae, most importantly portal vein thrombosis. In our study, heterogeneous pancreatic contrast enhancement and portal vein thrombosis were strongly correlated, and portal vein thrombosis was significantly more likely to be detected by CTA than US.
Portal vein thrombosis may be the result of a coagulopathy associated with pancreatitis or other comorbidities or a consequence of local endothelial injury secondary to regional inflammation. 21, 22 In the cranial abdomen, the portal vein lies in close proximity to the pancreas just before entering the liver. The majority of the patients in our study developed thrombi immediately adjacent to the body of the pancreas within the main portal vein. Given the anatomy of this region and the surrounding structures, it is not surprising that portal vein thrombi were not commonly detected by US because this area is deep in the abdomen. In addition, most patients undergoing US for acute pancreatitis are severely painful in the cranial abdomen and have other pathologic changes associated with this disease that make evaluation of the cranial abdomen difficult, such as gastric ileus, peritoneal effusion, regional steatitis, and peritonitis, all of which may attenuate the US beam. 23 Portal vein thrombosis was detected by US in only 1 of the 26 (4%) dogs in our study.
In a previous study evaluating risk factors in dogs with fatal acute pancreatitis, 96% of dogs had evidence of pancreatic necrosis at necropsy. 24 Thrombus formation also was found more commonly in dogs with fatal acute pancreatitis than in control dogs. 24 This finding is consistent with the human medical literature that has not only shown higher mortality and morbidity in patients with evidence of pancreatic necrosis on CTA but also has shown a strong correlation between these variables and extent of pancreatic necrosis. A previous report
showed that human patients with <30% necrosis had 0% mortality and 48% morbidity, whereas those patients with >30% necrosis had morbidity of 94% and mortality of 29%. 7, 8 In our study, heterogeneous contrast enhancement and portal vein thrombosis were both significantly associated with longer hospitalization, with the majority of these patients being hospitalized for >5 days. These findings may be useful to determine treatment recommendations for dogs with more severe forms of pancreatitis and to advise owners of duration of hospitalization and possible complications.
Interestingly, 2 of the 4 dogs that died or were euthanized during the acute stage of disease also were dogs with heterogeneous contrast enhancement of all portions of the pancreas (ie, right lobe, left lobe, and body). One of those dogs had severe focal infarction of the proximal duodenum resulting in duodenal necrosis and subsequent perforation ( Figure 4 ). Necropsy and histopathology confirmed that this dog was suffering from acute, extensive, necrosuppurative pancreatitis with hemorrhage and fat necrosis. In addition, gastritis, hepatitis, and severe cholestasis with possible necrosis of the bile duct were identified at necropsy. This type of duodenal infarction also was reported in a previous clinicopathologic survey of dogs and cats with pancreatitis. In that study, a single dog had complete infarction of the cranial mesenteric artery with gangrenous necrosis of the proximal duodenum. 25 Identifying diffuse heterogeneous pancreatic enhancement on CTA may indicate a grave prognosis in dogs with acute pancreatitis.
Finally, those dogs with heterogeneous contrast enhancement had significantly increased median spec cPL compared to dogs with homogeneous contrast enhancement. The median result in dogs with heterogeneous contrast enhancement was 1631.5 μg/L compared to 381 μg/L in dogs with homogeneous contrast enhancement. This finding is interesting because it is the 1st time that a correlation between CT findings and a pancreatic serum assay has been noted.
Outside histopathology, the spec cPL test has been shown in multiple studies to be the most sensitive and specific indicator of pancreatic acinar cell damage, with previously reported sensitivity and specificity of 71.7%-77.8% and 80.5%-88.0%, respectively. 4, 26, 27 This informa- Additional findings in our study that were unexpected were the increased detection of biliary mineralization by CTA and the significantly longer hospitalization and longer time until death seen with lymphadenomegaly. Biliary mineralization was most commonly in the form of sediment or "sand-like" cholelithiasis, with no dogs in our study having larger choleliths. Cholelithiasis previously has been associated with biliary stasis, altered dietary composition, and cholecystitis. [28] [29] [30] Whether this finding is a result of decreased gall bladder emptying or inflammation associated with pancreatitis or is associated with some comorbidity that may contribute to both diseases is unknown, but previous studies have shown pancreatitis to be the most common cause of extra-luminal biliary tract obstruction. 30 Because US is considered a good diagnostic tool for detecting cholelithiasis, this finding was surprising. Perhaps, the better soft tissue resolution of CT and the non-dependence on patient comfort and compliance as well as the small volume of mineralization in most dogs played a role in the better detection of biliary mineralization by CT imaging.
Based on CT imaging, 11 of the 26 dogs in our study had lymph node enlargement. The most commonly affected nodes were the hepatic, pancreaticoduodenal, and mesenteric. None of the affected nodes were sampled, but all lymph nodes were mildly enlarged with normal smooth contour and normal homogeneous parenchyma, which have been shown to be more consistent with reactive lymphadenopathy. 15, 31, 32 The correlation between lymphadenomegaly and longer hospitalization time likely indicates a stronger immune and inflammatory response in those animals with more severe pancreatitis. The longer time until death in these patients was, however, unexpected. We suspect this finding is likely the result of small sample size and the fact that a large number of patients survived beyond the acute stage of the disease, were lost to follow-up, or both. Necropsy and histopathology confirmed that this dog was suffering from acute, extensive, necrosuppurative pancreatitis with hemorrhage, and fat necrosis.
A shorter time until death was expected but not found in patients with pancreatic necrosis, portal vein thrombosis, or both. This result was also likely a consequence of the small sample size and the large number of animals that were lost to follow-up. Additional notable sequelae that were identified in a number of animals by both CT and US included gastric and intestinal wall thickening, likely secondary to regional inflammation, biliary dilatation, and peritoneal effusion.
One of the major limitations of our study was the lack of histopathology of the pancreas and definitive confirmation of thrombosis in the majority of patients. The only patients in which histopathology results were available were the relatively few animals that died or were euthanized as a consequence of their disease, but CTA findings were confirmed in these dogs. Histopathology is the gold standard for diagnosis of pancreatic necrosis, but studies have shown the negative complications associated with surgical biopsy of the pancreas, and it is commonly accepted that pancreatic biopsy during acute pancreatitis may further injure the pancreas. 33, 34 Alternatively, FNA of the pancreas is a safe and easy procedure. In a previous study of healthy Beagles undergoing both fine needle and clamshell biopsy of the pancreas, no increase in serum trypsin-like immunoreactivity was observed after FNA of the pancreas, whereas an increase occurred after surgical biopsy. 35 An additional study of 73 cats with clinical or sonographic evidence of pancreatic disease undergoing FNA of the pancreas showed no increased risk of complications when compared to cats undergoing FNA of other organs or when compared to control cats. 36 Another limitation of our study was the variability of clinician experience in performing US examinations. Ultrasonography is a highly operator-dependent modality. This factor may have influenced the overall ability of US to evaluate all regions of the pancreas. It is a standard practice in our institution that all US scans performed by a radiology resident are carefully reviewed by a staff radiologist and complicated examinations or examinations in which not all organs are visualized usually are repeated by a staff radiologist. In addition, it was our intention to limit the degree of intervention in the clinical course of these patients, because we wanted to mimic the normal clinical examination as closely as possible.
A final limitation was the lack of blinding of the imaging studies.
Both reviewers knew these dogs were suspected to have pancreatitis based on enrollment in the study, which introduced an inherent bias.
However, all studies were reviewed months after enrollment to minimize recall of the initial imaging findings.
In conclusion, CTA identified dogs with a heterogeneously contrastenhancing pancreas, a more severe form of acute pancreatitis. Heterogeneous pancreatic enhancement along with portal vein thrombosis may predict longer hospitalization and increased risk of relapse, which may affect the clinical management of patients with acute pancreatitis.
Our findings support the use of CTA as an additional and superior diagnostic modality in the evaluation of acute pancreatitis in dogs. 
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